Overexpression of ELL-associated factor 2 suppresses invasion, migration, and angiogenesis in colorectal cancer

Table 2 Baseline characteristics of patients with advanced colorectal cancer and their correlation with immunohistochemical expression of ELL-associated factor 2

Clinicopathologic characteristic	Cases, n (%)	EAF2		P value
		Low (n = 58)	High (n = 12)
Age (yr)				0.831
< 61 (median)	47.14	27	6
≥ 61	52.86	31	6
Gender				0.589
Male	57.14	34	6
Female	42.86	24	6
Tumor site				0.162
Colon	34.29	22	2
Rectum	65.71	36	10
Size of the tumor (cm)				0.726
≤ 4	37.14	21	5
> 4	62.86	37	7
Histological type				0.210
Mucinous	20.00	10	4
Non-mucinous	80.00	48	8
Degree of differentiation				0.318
Well/moderate	62.86	38	6
Poor/mucinous	37.14	20	6
Angiolymphatic and/or perineural invasion				0.113
Absent	45.71	24	8
Present	54.29	34	4
Tumor stage (TNM)				0.240
I-II	42.86	23	7
III-IV	57.14	35	5
Tumor invasion depth				0.682
T2-T3	52.86	30	7
T4	47.14	28	5
Lymph node status				0.210
N0	50.00	27	8
N1-N2	50.00	31	4
Distant metastasis				0.025
Absent	74.29	40	12
Present	25.71	18	0
CEA				0.038
Normal	65.71	35	11
High	34.29	23	1
CA19-9				0.445
Normal	40.00	22	6
High	60.00	36	6
P53				0.589
Normal	42.86	24	6
High	57.14	34	6
CDX2				0.350
Normal	22.86	12	4
High	77.14	46	8

EAF2: ELL-associated factor 2; TNM: Tumor-node-metastasis; CEA: Carcinoembryonic antigen; CA19-9: Carbohydrate antigen 19-9.